The WHO Mental Health Gap Action Programme (mhGAP) aims at scaling up services for mental, neurological and substance use disorders for countries especially with low- and middle-income. The programme asserts that with proper care, psychosocial assistance and medication, tens of millions could be treated for depression, schizophrenia, and epilepsy, prevented from suicide and begin to lead normal lives– even where resources are scarce.
The PosiFects platform has been developed to track and log both the negative and beneficial side effects of both psychological and pharmacological treatments, for a wide range of health conditions in real-time.
It is an exploratory study for Suicidal Ideation: A Multicentre, Two Arm, Randomized Controlled Trial From Pakistan to determine the feasibility, acceptability and efficacy of an adapted digitally delivered CMAP (CMAP-SI) intervention (CAMI) compared to treatment as usual (TAU) for patients presenting with suicidal ideation.
This is a mixed-methods study. The quantitative component will comprise of a multicentre rater-blind, randomized controlled trial to evaluate the feasibility and acceptability of AISHA in addition to treatment as usual (TAU) compared to TAU alone in Pakistan.
In-depth interviews and focus groups with other stakeholders will take place to consider the wider implementation of AISHA in mental health services in Pakistan.
Mobile-AssessmenT and ThErapy for PsyCHosis: An intervention for Clients within the EArly InteRvention Service: Improving mental health and tackling health inequalities. In this study Mobile phone App, developed as part of a feasibility trial. The TechCare App uses an integrated momentary sampling assessment approach that is matched with a psychological intervention in real-time to address low mood and paranoia.